- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01987297
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is carried out based on Sanz risk stratification of newly-diagnosed APL patients into low-, intermediate- and high-risk groups, and all of them will receive ATRA and ATO as induction therapy (ATRA 25 mg/m2 per day orally + ATO 0.16mg/kg intravenously daily). Anthracycline is added to both high-risk groups or intermediate-risk group with hyperleukocytosis developed during induction therapy but not in low-risk groups.
After achieving CR, patients enter into consolidation therapy. Low-risk patients receive either 2 courses of ATRA plus ATO (Experimental group) or 2 courses of ATRA plus anthracycline chemotherapy (Control group). Intermediate-risk patients receive either 3 courses of ATRA plus ATO (Experimental group) or 2 courses of ATRA plus anthracycline chemotherapy (Control group). Patients of high-risk disease receive 2 courses of ATRA plus ATO and anthracycline and 1 course of ATRA plus ATO treatment (Experimental group) or 2 courses of ATRA plus anthracycline and cytarabine and 1 course of ATRA plus mid-dose cytarabine (Control group).
After consolidation therapy, patients with molecular complete remission (mCR) enter into maintenance therapy. Low- and intermediate-risk patients receive 3 cycles of ATRA and ATO sequential treatment, while those of high-risk receive 5 cycles of ATRA, ATO and methotrexate (MTX) treatment.
For low- and intermediate-risk patients who fail to achieve mCR after consolidation therapy, 3 courses of consolidation therapy of high-risk group will be given with cross-over (i.e. patients in Experimental group received the therapy of Control group, and patients in Control group received the therapy of Experimental group). If patients still fail to achieve mCR, together with high-risk group who fail to achieve mCR after consolidation therapy will be withdrawn from the study and proceed to salvage treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200025
- Department of Hematology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly-diagnosed patients with acute promyelocytic leukemia via cytogenetics and molecular assay
- Age: 18-65
- Hepatic/renal function: Bil≤35μmol/L,AST/ALT less than 2Xnormal range, Cr 150μmol/L
- Normal cardial function
- ECOG:0-4
- Informed consent
Exclusion Criteria:
- QTC interval >450ms
- Pregnant or breast feeding patients
- Patients with drug addiction or mental illness
- Patients documented of CNS infiltration at diagnosis
- Patients with severe heart disease (acute myocardial infarction or heart failure)
- Patients with concurrent active malignancy, tuberculosis or HIV infection
- Patients with contraindication or allergy to anthracyclines or other agent in the protocol
- Patients enrolled in other clinical trials
- Patients not apply to the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATRA+Arsenic
All low- and intermediate-risk patients receive retinoic acid and arsenic trioxide based consolidation.
High-risk patients receive ATRA+Arsenic+Anthracycline consolidation.
|
ATRA: 25mg/m2 daily;Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course. Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course. Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses. MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients.
Other Names:
|
Active Comparator: ATRA+chemo
All low-risk and intermediate-risk patients receive retinoic acid and chemotherapy with idarubicin or daunorubicin as consolidation.
High-risk patients receive ATRA+anthracycline and cytarabine as consolidation.
|
ATRA: 25mg/m2 daily;Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course. Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course. Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses. Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course. MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free survival (DFS)
Time Frame: 3 year
|
DFS is defined for patients having achieve CR as time to relapse either in bone marrow or extra medullary site, or fail to achieve molecular remission, or death of all causes.
|
3 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remission (CR) rate
Time Frame: after induction therapy
|
Blast and promyelocytic leukemia less than 5% in bone marrow
|
after induction therapy
|
Molecular CR (mCR)
Time Frame: after consolidation therapy
|
mCR is defined the absence of detectable PML-RARα transcripts by nested RT-PCR or RQ-PCR in two successive bone marrow samples
|
after consolidation therapy
|
Early death (ED) rate
Time Frame: 30 days
|
Early death is referred to death within 30 days from the entry into the treatment.
|
30 days
|
Overall survival (OS)
Time Frame: 3 years
|
OS is defined for patients entering the study as time to death of all causes.
|
3 years
|
Cumulated incidence of relapse (CIR)
Time Frame: 3 years
|
CIR is defined for patients having achieved CR as time to any relapse or persistence of PCR positivity after consolidation therapy
|
3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematological or non hematological toxicitytoxicitie
Time Frame: 3 years
|
Assessed according to the Common Terminology Criteria for Adverse Events Version 4.0 (National Cancer Institute)
|
3 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jun-min Li, M.D, Department of Hematology, Rui Jin Hospital, Shanghai JiaoTong University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia
- Leukemia, Promyelocytic, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Keratolytic Agents
- Arsenic Trioxide
- Cytarabine
- Daunorubicin
- Idarubicin
- Tretinoin
Other Study ID Numbers
- APL2012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Promyelocytic Leukemia
-
German AML Cooperative GroupUnknownRelapsed Acute Promyelocytic Leukemia | Refractory Acute Promyelocytic LeukemiaGermany
-
Christian Medical College, Vellore, IndiaUnknownRelapsed Acute Promyelocytic LeukemiaIndia
-
Instituto Nacional de Cancerologia de MexicoCompletedPromyelocytic Leukemia, AcuteMexico
-
PETHEMA FoundationCompletedAcute Promyelocytic LeukemiaSpain
-
South China Children's Leukemia GroupCompletedChildhood Acute Promyelocytic LeukemiaChina
-
Peking University People's HospitalMinistry of Science and Technology of the People´s Republic of ChinaNot yet recruitingAcute Promyelocytic Leukaemia
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAUnited States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
-
Grupo Argentino de Tratamiento de la Leucemia AgudaRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARAUnited States
-
The University of Hong KongRecruitingAcute Promyelocytic LeukemiaHong Kong
Clinical Trials on ATRA+Arsenic
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Promyelocytic LeukemiaItaly
-
PETHEMA FoundationCompletedAcute Promyelocytic LeukemiaSpain
-
The University of Hong KongRecruitingAcute Promyelocytic LeukemiaHong Kong
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingAcute Myeloid LeukemiaChina
-
National Cancer Institute (NCI)TerminatedAdenocarcinoma of the Esophagus | Stage IV Esophageal Cancer | Stage III Esophageal CancerUnited States
-
Stanford UniversityThe V Foundation for Cancer ResearchCompletedRecurrent Skin Cancer | Basal Cell Carcinoma of the SkinUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral CancerUnited States
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions
-
National Cancer Institute (NCI)TerminatedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditionsUnited States